熱點掃描 | 黃金及貴金屬板塊拉升，紫金礦業漲超7%
uSMART盈立智投4月13日消息，截止發稿，港股三大指數齊漲，恆生指數上漲0.25%，報21372.45點，成交額448.84億；國企指數上漲0.66%，報7312.59點，成交額150.32億；紅籌指數上漲1.37%，報4042.93點，成交額23.28億。
黃金及貴金屬板塊拉昇，紫金礦業漲超7%，中國黃金國際漲逾6%，招金礦業漲超4%，山東黃金、靈寶黃金跟漲；
煤炭股漲幅居前，伊泰煤炭、兗礦能源漲超7%，中煤能源漲超6%,易大宗、蒙古焦煤漲超4%；
海運板塊走強，中國外運漲超6%，中遠海能漲3%，中遠海控、太平洋航運、東方海外國際跟漲；
醫藥外包概念股走低，金斯瑞生物科技跌超4%，藥明康德、藥明生物跌3%，康龍化成跌逾2%；
熱門股
洛陽鉬業漲超5%，報4.43港元，該公司昨日發佈公告，今年一季度，公司位於剛果（金）的TFM銅產量實現計劃的103%，鈷產量實現計劃的110%，全面超額完成一季度生產目標任務。2022年，TFM計劃實現銅產量22.7萬-26.7萬噸，鈷產量1.75萬-2.05萬噸。目前，總投資額超25億美元的TFM混合礦開發項目正按裏程碑計劃順利推進。2023年建成後，TFM將新增產能銅金屬超20萬噸/年，鈷金屬超1.7萬噸/年，實現再造一個TFM。
中國旭陽集團漲逾4%，報4.07港元，中國旭陽集團昨日公告，於公告日，董事會正式決議行使股份購回授權，在2022財政年度不定期最高總額港幣3億元於公開市場購回股份。公司將根據本公司組織章程細則、香港聯合交易所有限公司證券上市規則、公司收購、合併及股份回購守則、開曼羣島公司法以及所有其他適用法律及法規進行建議股份購回。董事會認爲，建議股份購回可反映董事會對公司的長期策略及發展充滿信心。董事會認爲，建議股份購回符合公司及股東的整體最佳利益。
榮昌生物跌幅擴大至8.7%，盤中低見36.9港元，再度刷新歷史低價，大和報告稱，考慮到與Seagen的分成收入低於預期，加上疫情對藥品銷售影響，下調榮昌生物今年收入25%，目標價由114港元下調至92港元。另外，公司管理層可能在今年下半年啓動針對膀胱癌而注射維迪西妥單抗(RC48)的臨牀試驗，該行認爲其目標收入可能會低於預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
